K
Kim Kramer
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 154
Citations - 5995
Kim Kramer is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Neuroblastoma & Radioimmunotherapy. The author has an hindex of 40, co-authored 139 publications receiving 4969 citations. Previous affiliations of Kim Kramer include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Ayuko Hoshino,Ayuko Hoshino,Han Sang Kim,Han Sang Kim,Linda Bojmar,Linda Bojmar,Linda Bojmar,Kofi Ennu Gyan,Michele Cioffi,Jonathan M. Hernandez,Jonathan M. Hernandez,Jonathan M. Hernandez,Constantinos P. Zambirinis,Constantinos P. Zambirinis,Gonçalo Rodrigues,Gonçalo Rodrigues,Henrik Molina,Søren Heissel,Milica Tesic Mark,Loïc Steiner,Loïc Steiner,Alberto Benito-Martin,Serena Lucotti,Angela Di Giannatale,Katharine Offer,Miho Nakajima,Caitlin Williams,Laura Nogués,Laura Nogués,Fanny A. Pelissier Vatter,Ayako Hashimoto,Ayako Hashimoto,Ayako Hashimoto,Alexander E. Davies,Daniela Freitas,Daniela Freitas,Candia M. Kenific,Yonathan Ararso,Weston Buehring,Pernille Lauritzen,Yusuke Ogitani,Kei Sugiura,Kei Sugiura,Naoko Takahashi,Maša Alečković,Kayleen A. Bailey,Joshua S. Jolissant,Joshua S. Jolissant,Huajuan Wang,Ashton Harris,L. Miles Schaeffer,Guillermo García-Santos,Guillermo García-Santos,Zoe Posner,Vinod P. Balachandran,Yasmin Khakoo,G. Praveen Raju,Avigdor Scherz,Irit Sagi,Ruth Scherz-Shouval,Yosef Yarden,Moshe Oren,Mahathi Malladi,Mary Petriccione,Kevin C. De Braganca,Maria Donzelli,Cheryl Fischer,Stephanie Vitolano,Geraldine P. Wright,Lee Ganshaw,Mariel Marrano,Amina Ahmed,Joe DeStefano,Enrico Danzer,Michael H.A. Roehrl,Norman J. Lacayo,Theresa C. Vincent,Theresa C. Vincent,Martin R. Weiser,Mary S. Brady,Paul A. Meyers,Leonard H. Wexler,Srikanth R. Ambati,Alexander J. Chou,Emily K. Slotkin,Shakeel Modak,Stephen S. Roberts,Ellen M. Basu,Daniel Diolaiti,Benjamin A. Krantz,Benjamin A. Krantz,Fatima Cardoso,Amber L. Simpson,Michael F. Berger,Charles M. Rudin,Diane M. Simeone,Maneesh Jain,Cyrus M. Ghajar,Surinder K. Batra,Ben Z. Stanger,Jack D. Bui,Kristy A. Brown,Vinagolu K. Rajasekhar,John H. Healey,Maria de Sousa,Maria de Sousa,Kim Kramer,Sujit Sheth,Jeanine Baisch,Virginia Pascual,Todd E. Heaton,Michael P. La Quaglia,David J. Pisapia,Robert E. Schwartz,Haiying Zhang,Yuan Liu,Arti Shukla,Laurence Blavier,Yves A. DeClerck,Mark A. LaBarge,Mina J. Bissell,Thomas C. Caffrey,Paul M. Grandgenett,Michael A. Hollingsworth,Jacqueline Bromberg,Jacqueline Bromberg,Bruno Costa-Silva,Héctor Peinado,Yibin Kang,Benjamin A. Garcia,Eileen M. O'Reilly,David P. Kelsen,Tanya M. Trippett,David R. Jones,Irina Matei,William R. Jarnagin,David Lyden +136 more
TL;DR: EVP proteins can serve as reliable biomarkers for cancer detection and determining cancer type, and a panel of tumor-type-specific EVP proteins in TEs and plasma are defined, which can classify tumors of unknown primary origin.
Journal ArticleDOI
Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma
TL;DR: 3F8/GM-CSF is well tolerated and shows promise for treatment of minimal residual NB in BM, and side effects were limited to readily manageable pain and rash of short duration.
Journal ArticleDOI
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.
Kim Kramer,Brian H. Kushner,Shakeel Modak,Neeta Pandit-Taskar,Peter Smith-Jones,Pat Zanzonico,John L. Humm,Hong Xu,Suzanne L. Wolden,Mark M. Souweidane,Steven M. Larson,Nai-Kong V. Cheung +11 more
TL;DR: The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies, and has the potential to increase survival with better than expected quality of life.
Journal ArticleDOI
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
Nai-Kong V. Cheung,Irene Y. Cheung,Brian H. Kushner,Irina Ostrovnaya,Elizabeth Chamberlain,Kim Kramer,Shakeel Modak +6 more
TL;DR: Retrospective analysis of consecutive trials from a single center demonstrated that MoAb 3F8 + GM-CSF + CRA is effective against chemotherapy-resistant marrow MRD.
Journal ArticleDOI
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial
Mark M. Souweidane,Mark M. Souweidane,Kim Kramer,Kim Kramer,Neeta Pandit-Taskar,Neeta Pandit-Taskar,Zhiping Zhou,Zhiping Zhou,Sofia Haque,Sofia Haque,Pat Zanzonico,Jorge A. Carrasquillo,Jorge A. Carrasquillo,Serge K. Lyashchenko,Serge K. Lyashchenko,Sunitha B. Thakur,Maria Donzelli,Ryan S Turner,Jason S. Lewis,Nai-Kong V. Cheung,Steven M. Larson,Ira J. Dunkel,Ira J. Dunkel +22 more
TL;DR: PET-based dosimetry of the radiolabelled antibody [124I]-8H9 validated the principle of using convection-enhanced delivery in the brain to achieve high intra-lesional dosing with negligible systemic exposure in children with diffuse intrinsic pontine glioma.